Nonmydriatic imaging useful in diabetic children

Article

Ophthalmologists may use nonmydriatic retinal imaging to supplement the standard clinical exam to screen diabetic children aged as young as 2 years, according to newly published research.

Ophthalmologists may use nonmydriatic retinal imaging to supplement the standard clinical exam to screen diabetic children aged as young as 2 years, according to newly published research.

US researchers conducted a prospective study of 106 children with type 1 diabetes who were aged 2 to 17 years. The study included an intake form; blood pressure, pulse and oximetry measurements; visual acuity assessment (Simav, Padova) and nonmydriatic colour imaging (CX-1 45° 15.1 megapixel camera, Canon). They assessed images for indications of diabetic retinopathy, and two clinicians graded image quality on a scale of 1 to 5.

Ninety-eight percent of the children underwent imaging. One was found to have nonproliferative diabetic retinopathy, and findings for 2 were incidental.

Sixty-two percent of the children had had an eye exam within the past year, with exams significantly more likely among older children and those who had had type 1 diabetes for more than 5 years.

Investigators graded images as high quality in 178 (86%) eyes, and they said images of some clinical value were obtained in 207 (99.5%) eyes.

The researchers shared their results in the Journal of Pediatric Ophthalmology and Strabismus.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.